Reaction
Dermatophytosis reporting signals
As of the last recalculation, Dermatophytosis appears in 282 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is VALGANCICLOVIR HYDROCHLORIDE POWDER, (PRR 144.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Valganciclovir Hydrochloride Powder, | 22 | 144.3 | 144.6 |
| Valganciclovir | 22 | 93.3 | 93.4 |
| Valganciclovir Hydrochloride | 22 | 93.3 | 93.4 |
| Tacrolimus Ointment 0.1% | 100 | 91.3 | 91.4 |
| Tacrolimus Extended-Release Capsules | 100 | 91.0 | 91.1 |
| Tacrolimus | 110 | 84.3 | 84.4 |
| Terbinafine Hydrochloride | 9 | 77.2 | 77.3 |
| Mycophenilic Acid | 20 | 76.6 | 76.7 |
| Itraconazole | 10 | 65.5 | 65.5 |
| Posaconazole Delayed-Release | 8 | 55.3 | 55.3 |
| Posaconazole | 8 | 37.4 | 37.4 |
| Daptomycin | 3 | 24.2 | 24.3 |